Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• High-risk neuroblastoma has a poor prognosis despite current treatments.
• Neuroblastoma RAS (NRAS) mutations are identified in a subset of patients, presenting a potential therapeutic target.
• Limited research exists on targeted therapies for NRAS-mutant neuroblastoma.

Purpose of the Study:

• To investigate the efficacy of MEK and mTOR inhibitors in NRAS-mutant neuroblastoma.
• To explore combination therapies involving MEK, PI3K, AKT, and mTOR inhibitors.
• To identify potential therapeutic strategies for NRAS-mutant neuroblastoma.

Main Methods:

• In vitro study using neuroblastoma cell lines with NRAS mutations and wild-type NRAS.
• Treatment with MEK inhibitors (AZD6244, MEK162, PD0325901).
• Treatment with PI3K, AKT, mTOR (Everolimus, AZD8055) inhibitors, and combinations thereof.

Main Results:

• MEK inhibitors blocked cell growth in NRAS-mutant cell lines but not wild-type.
• Combined MEK and PI3K/AKT inhibition did not show synergistic effects.
• mTOR inhibitors Everolimus and AZD8055 alone inhibited NRAS-mutant cell growth and induced apoptosis.
• Combination of mTOR and MEK inhibitors demonstrated synergistic growth inhibition.

Conclusions:

• NRAS-mutant neuroblastoma is susceptible to MEK and mTOR inhibitors.
• Everolimus alone is effective against NRAS-mutant neuroblastoma.
• Combination therapy with mTOR and MEK inhibitors shows synergistic efficacy.
• These findings support the clinical investigation of Everolimus and MEK inhibitors for NRAS-mutant neuroblastoma.